Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ALPHAMAB ONCOLOGY
康寧傑瑞生物製藥
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9966)

VOLUNTARY ANNOUNCEMENT
FIRST PATIENT DOSED IN PHASE III CLINICAL STUDY OF JSKN033 MONOTHERAPY FOR THE TREATMENT OF CERVICAL CANCER

This announcement is made by Alphamab Oncology (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders (the "**Shareholders**") and potential investors of the Group about the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the first patient has been successfully dosed in a phase III clinical study of JSKN033 (a high-concentration subcutaneous co-formulation consisting of a human epidermal growth factor receptor 2 ("**HER2**") bispecific antibody-drug conjugate ("**ADC(s)**") and a programmed death ligand 1 ("**PD-L1**") immune checkpoint inhibitor) as monotherapy for patients with recurrent or metastatic cervical cancer who have failed platinum-based chemotherapy and PD-1/PD-L1 inhibitor treatment, irrespective of HER2 and PD-L1 expression levels (study number: JSKN033-301).

Cervical cancer remains the most common gynecological malignancy worldwide and the fourth leading cause of cancer-related death among women. Patients with locally advanced and those with high-risk early-stage cervical cancer frequently experience relapse and develop distant metastases, and the five-year survival rate for advanced cervical cancer is below 20%. The current first-line standard of care — immunotherapy combined with platinum-based doublet chemotherapy, with or without bevacizumab — is recommended by both Chinese and international guidelines; however, acquired resistance ultimately leads to disease progression in the majority of patients. For patients with cervical cancer whose disease has progressed following both platinum-based chemotherapy and PD-1/PD-L1 inhibitor treatment, only single-agent chemotherapy, such as docetaxel, is currently available, with an objective response rate of only approximately 10%, highlighting a substantial unmet clinical need.

JSKN033-301 is a randomized, controlled, open-label, multicenter phase III clinical study to evaluate the efficacy and safety of JSKN033 compared with physician's choice of chemotherapy in patients with recurrent or metastatic cervical cancer who have failed platinum-based chemotherapy and PD-1/PD-L1 inhibitor treatment, irrespective of HER2 and PD-L1 expression levels. The primary endpoints are progression-free survival as assessed by blinded independent central review ("**BICR**") in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and overall survival. The secondary endpoints include other efficacy endpoints assessed by BICR and investigators in accordance with RECIST v1.1, safety and pharmacokinetic characteristics.

As the world's first and currently only subcutaneous ADC co-formulation to enter registrational clinical studies, JSKN033 enables administration in a matter of seconds, greatly enhancing convenience of administration and patient compliance. It also offers the synergistic advantages of targeted therapy and immunotherapy and has the potential to provide a novel "targeted therapy + immunotherapy" treatment regimen for patients with cervical cancer. JSKN033 monotherapy has demonstrated outstanding efficacy and a manageable safety profile in patients with cervical cancer following failure of standard treatment. Detailed data were presented as a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress held in October 2026. For details, please refer to the announcement of the Company dated October 26, 2026.

ABOUT JSKN033

JSKN033 is a global first high-concentration subcutaneous co-formulation with JSKN003, the HER2 bispecific ADC and Envafolimab, the PD-L1 single domain antibody, developed by the Group. JSKN003 is a biparatopic HER2-targeting ADC, of which a topoisomerase I inhibitor is linked to the N glycosylation site of Anbenitamab (KN026) (a recombinant humanized anti-HER2 bispecific antibody) via the glycosite-specific conjugation. Envafolimab is a Fc fusion protein consisting of humanized anti-PD-L1 single domain antibody and human Immunoglobulin G1 Fc fragment, which has been approved by the National Medical Products Administration of China (國家藥品監督管理局) (the "**NMPA**") as the global-first subcutaneous injection PD-L1 inhibitor in November 2021.

JSKN033 combines the benefits of immunotherapy and ADCs while enhancing safety and convenience through subcutaneous administration. Currently, multiple phase II clinical studies are progressing smoothly, including studies of JSKN033 in combination with platinum-based chemotherapy as first-line treatment for advanced cervical cancer and JSKN033 monotherapy as second-line or later treatment for cervical cancer and endometrial cancer. A phase III clinical study of JSKN033 monotherapy for the treatment of recurrent or metastatic cervical cancer following failure of platinum-based chemotherapy and PD-1/PD-L1 inhibitor treatment has also been initiated.

ABOUT THE COMPANY

The Company is a leading biopharmaceutical company in the PRC with a fully integrated proprietary technology platform in ADCs, bispecific antibodies and multi-functional protein engineering. The Company's highly differentiated in-house pipeline consists of ADCs, monoclonal antibodies and bispecific antibodies in staggered development status in oncology, including, among others, two products approved for marketing by the NMPA and multiple products in phase III or pivotal clinical trial stages. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefiting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological drug candidates that could potentially benefit patients globally.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop and/or ultimately market JSKN033 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, October 28, 2026

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.